HIV research on monkeys makes breakthrough

A single shot of antiretroviral drugs protected lab monkeys from HIV for weeks, according to two US trials released on Tuesday that open the way to tests on humans.

In separate work, two teams of virologists found that monkeys that received a monthly injection of a prototype drug were completely shielded from the simian equivalent of HIV.

The research builds on previous trials showing that people who take a small daily doses of antiretroviral drugs can slash their risk of being infected by an HIV-positive partner by more than 90%.

But this protection was far lower when participants failed to take the drugs each day, highlighting the need for a monthly or quarterly injection to avert the problem.

In one of the studies, conducted at the US Centres for Disease Control and Prevention (CDC), researchers gave a monthly shot of an experimental, delayed-effect antiretroviral drug called GSK744 to six female monkeys.

Twice a week they inserted into their vagina a liquid containing a human-simian immunodeficiency virus to simulate their having had intercourse with an infected male.

None of the females treated with GSK744 became infected, but six from a control group that were treated with a placebo all became infected quickly.

No infection
The other researchers, from the Aaron Diamond Aids Research Centre at the Rockefeller University in New York, tested the same drug on 15 monkeys, but this time exposing them to the risk of anal infection.

The results were identical – none of the treated animals was infected, but all those on placebo were infected.

A first clinical trial with 175 people is expected to begin later this year in the United States, Brazil, South Africa and Malawi with GSK744, which was developed by the British pharmaceutical firm GlaxoSmithKline.

The data was presented at the Conference on Retroviruses and Opportunistic Infections, in Boston. – AFP

Bhekisisa team
Bhekisisa Team
Health features and news from across Africa by Bhekisisa, the Mail & Guardian's health journalism centre.
Advertisting

Senior SANDF colonel involved in an alleged business scam

A senior soldier who is part of South Africa’s peacekeeping missions is accused by her colleagues of swindling them out of of hundreds of thousands of rands in a nonexistent business deal

AU pushes the frontiers of transitional justice

Now these important policy developments must be implemented

Mass store and job cuts at Massmart

Changed market conditions and an appalling economy has hit low end cash-and-carry outlets

Courts to guide land expropriation

Two bits of law need to be approved before a court can decide if land owners will be compensated
Advertising

Press Releases

New-style star accretion bursts dazzle astronomers

Associate Professor James O Chibueze and Dr SP van den Heever are part of an international team of astronomers studying the G358-MM1 high-mass protostar.

2020 risk outlook: Use GRC to build resilience

GRC activities can be used profitably to develop an integrated risk picture and response, says ContinuitySA.

MTN voted best mobile network

An independent report found MTN to be the best mobile network in SA in the fourth quarter of 2019.

Is your tertiary institution is accredited?

Rosebank College is an educational brand of The Independent Institute of Education, which is registered with the Department of Higher Education and Training.

Is your tertiary institution accredited?

Rosebank College is an educational brand of The Independent Institute of Education, which is registered with the Department of Higher Education and Training.

VUT chancellor, Dr Xolani Mkhwanazi, dies

The university conferred the degree of Doctor of Science Honoris Causa on Dr Xolani Mkhwanazi for his outstanding leadership contributions to maths and science education development.

Innovate4AMR now in second year

SA's Team pill-Alert aims to tackle antimicrobial resistance by implementing their strategic intervention that ensures patients comply with treatment.

Medical students present solution in Geneva

Kapil Narain and Mohamed Hoosen Suleman were selected to present their strategic intervention to tackle antimicrobial resistance to an international panel of experts.